The usefulness of QuantiFERON CMV in an intermediated risk of CMV infection in kidney transplant recipient

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20200901006

Enrollment

Registered

2020-09-01

Start date

2020-08-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intermediated risk for CMV DNAemia after kidney transplant QuantiFERON CMV&#44

Interventions

All patient with met intermediated risk for CMV DNAemia after kidney transplantation included

Diagnostic

Intermediated risk for CMV DNAemia after kidney transplant

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age â‰¥ 18 year olds 2.Living or deceased donor kidney transplantation without preformed DSA 3.Low to intermediate risk for CMV infection after kidney transplantation

Exclusion criteria

Exclusion criteria: 1. White blood count < 1,500/mm3 2. Delay graft function with dialysis dependence) 3. Severe infection 4. Advanced malignancy 5. Pregnancy 6. Reject consent

Design outcomes

Primary

Measure	Time frame
ROC curve of QuantiFERON CMV on Incidence of CMV DNAemia at day 1 month after kidney transplantation and end of the study QuantiFERON CMV, CMV viral load	—

Secondary

Measure	Time frame
Sensitivity, specificity and accuracy of QuantiFERON CMV on incidence of CMV detection at day 1 month after kidney transplantation and end of the study QuantiFERON CMV, CMV viral load	—

Countries

Thailand

Contacts

Public ContactKamonwan Jutivorakool

King Chulalongkorn Memorial Hospital and Chulalongkorn University

kamojuti@gmail.com0649499551

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026